Inactive Instrument

News DiaMedica Therapeutics Inc. Toronto S.E.

Equities

DMA

CA25253X2077

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	Apr. 17	MT
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	Apr. 17	BU
DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	Apr. 17	CI
DiaMedica Therapeutics Inc. Announces Executive Changes	Apr. 10	CI
DiaMedica Therapeutics Files $100 Million Mixed Shelf	Mar. 21	MT
Craig Hallum Cuts DiaMedica Therapeutics Price Target to $8 From $11, Maintains Buy Rating	Mar. 21	MT
Oppenheimer Trims DiaMedica Therapeutics Price Target to $6 From $7, Maintains Outperform Rating	Mar. 21	MT
Transcript : DiaMedica Therapeutics Inc., 2023 Earnings Call, Mar 20, 2024	Mar. 20
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results	Mar. 19	BU
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference	Jan. 29	BU
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	Jan. 22	MT
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer	Jan. 22	BU
DiaMedica Therapeutics Inc. Appoints Dr. Lorianne Masuoka as Chief Medical Officer	Jan. 22	CI
Transcript : DiaMedica Therapeutics Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results	Nov. 13	BU
DiaMedica Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023	Nov. 09	BU
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023	Nov. 06	BU
Top Premarket Gainers	23-10-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News DiaMedica Therapeutics Inc. Toronto S.E.

Equities

DMA

CA25253X2077

Summary

Filters